Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Gynecology

Free Subscription Articles published in Cancer Retrieve available abstracts of 57 articles: HTML format

Single Articles

May 2025
1. DUSKA LR, Lim J, Calderon Boyle TA, Guinter M, et al
   The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?
   Cancer. 2025;131:e35821.
   PubMed     Abstract available
   
   
   
2. SCHNEIDER DT, Witowski A, Abele M, Benesch M, et al
   Testicular and ovarian Juvenile granulosa cell tumors in children and adolescents: Analysis of 113 patients registered to the German Registry for Rare Pediatric Tumors (STEP).
   Cancer. 2025;131:e35861.
   PubMed     Abstract available
   
   
   
3. HARRIS AK, Nelson AT, Watson D, Mallinger PHR, et al
   Ovarian juvenile granulosa cell tumor: A report from the International Ovarian and Testicular Stromal Tumor and International Pleuropulmonary Blastoma/DICER1 Registries.
   Cancer. 2025;131:e35862.
   PubMed     Abstract available
   
   
   
4. EBOTT J, Grant KR, Farley J, Stasenko M, et al
   Gender equity gap persists, addressing the root cause through the lens of gynecologic oncology: An evidenced-based review.
   Cancer. 2025;131:e35843.
   PubMed     Abstract available
   
   
   
5. HUANG CC, Ayala-Peacock DN, Stephens SJ, Chino JP, et al
   Recent advances in gynecologic radiation oncology.
   Cancer. 2025;131:e35888.
   PubMed     Abstract available
   
   
   April 2025
6. KUNOS CA, Chauhan A
   Prospects for radioimmunotherapy panaceas in gynecologic oncology.
   Cancer. 2025;131:e35841.
   PubMed    
   
   
   
7. FREY MK, Liu JF
   Shedding LIGHT on the changing landscape of poly-ADP ribose polymerase inhibitors in ovarian cancer.
   Cancer. 2025;131:e35800.
   PubMed    
   
   
   
8. APPLEBAUM JC, Ginsburg ES
   Parenthood after cancer: The critical, yet complex, contribution of gestational carriers.
   Cancer. 2025;131:e35853.
   PubMed    
   
   
   
9. ELLINGTON TD, Wardell AC, Deal AM, Mersereau J, et al
   In vitro fertilization with cryopreserved oocytes or embryos after cancer: The role of gestational carriers.
   Cancer. 2025;131:e35844.
   PubMed     Abstract available
   
   
   March 2025
10. RAYCHAUDHURI S, McLaughlin E, Pennell ML, Stefanick M, et al
    The relationship between cardiometabolic abnormalities and mortality in the Women's Health Initiative: A comparison of associations among women with cancer to women without cancer.
    Cancer. 2025;131:e35804.
    PubMed     Abstract available
    
    
    
11. KARPEL HC, Zambrano Guevara LM, Rimel BJ, Hacker KE, et al
    The missing data: A review of gender and sex disparities in research.
    Cancer. 2025;131:e35769.
    PubMed     Abstract available
    
    
    
12. SOROURI K, Glass K, Ruddy KJ, Warner E, et al
    Anti-Mullerian hormone for assessing ovarian toxicity of cancer treatment in young women: It's complicated.
    Cancer. 2025;131:e35774.
    PubMed    
    
    
    
13. BAE HS, Temkin SM
    Cervical cancer stigma - A silent barrier to the elimination of cervical cancer.
    Cancer. 2025;131:e35776.
    PubMed    
    
    
    
14. NIERENGARTEN MB
    More evidence on benefits of HIPEC for recurrent ovarian cancer.
    Cancer. 2025;131:e35754.
    PubMed    
    
    
    February 2025
15. PENNINX BMF, Samson MJ, Schnog JB
    Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III-IVa cervical cancer: is the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial practice changing?
    Cancer. 2025;131:e35749.
    PubMed     Abstract available
    
    
    
16. DUSKA LR, Petroni GR, Thaker PH, Crane EK, et al
    Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer.
    Cancer. 2025;131:e35757.
    PubMed     Abstract available
    
    
    
17. NIERENGARTEN MB
    New standard of care for patients with locally advanced cervical cancer.
    Cancer. 2025;131:e35739.
    PubMed    
    
    
    
18. BAEKER BISPO J, Jemal A, Islami F
    Association of mental health treatment receipt with cancer screening among US adults with a history of anxiety or depression.
    Cancer. 2025;131:e35724.
    PubMed     Abstract available
    
    
    
19. HIPPALGAONKAR N, Huo D, Hoskins KF
    The long road to unbiased estimates of pancreatic cancer incidence in the hereditary breast and ovarian cancer syndrome.
    Cancer. 2025;131:e35722.
    PubMed    
    
    
    
20. NERO C, Trozzi R, Persiani F, Rossi S, et al
    POLE mutations in endometrial carcinoma: Clinical and genomic landscape from a large prospective single-center cohort.
    Cancer. 2025;131:e35731.
    PubMed     Abstract available
    
    
    
21. TEMKIN SM
    Chronic conditions, cancer disparities, and the unique needs of Black women with ovarian cancer.
    Cancer. 2025;131:e35735.
    PubMed    
    
    
    January 2025
22. REN W, Guo X, Liu Z, Wu Y, et al
    Burden of female-specific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021.
    Cancer. 2025;131:e35712.
    PubMed     Abstract available
    
    
    
23. LIU YL, Mathews CA, Simpkins F, Cadoo KA, et al
    Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis.
    Cancer. 2025;131:e35707.
    PubMed     Abstract available
    
    
    
24. NIERENGARTEN MB
    Overall survival benefit of pembrolizumab plus chemoradiotherapy for patients with high-risk locally advanced cervical cancer.
    Cancer. 2025;131:e35688.
    PubMed    
    
    
    
25. MAHALINGAM D, Owonikoko TK, Delpassand E, Mulcahy MF, et al
    A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers.
    Cancer. 2025;131:e35680.
    PubMed     Abstract available
    
    
    
26. RICHARDS AR, Johnson CE, Montalvo NR, Alberg AJ, et al
    Comorbid conditions and survival among Black women with ovarian cancer.
    Cancer. 2025;131:e35694.
    PubMed     Abstract available
    
    
    
27. PANDEY AS, Drogan C, Huo D, Postula K, et al
    Anticipation in families with MLH1-associated Lynch syndrome.
    Cancer. 2025;131:e35589.
    PubMed     Abstract available
    
    
    December 2024
28. HENDRIX EL, Chollette VY, Wentzensen N, Loukissas JK, et al
    Federal Cervical Cancer Collaborative: Improving cervical cancer prevention through vaccination, screening, and management in safety-net settings of care.
    Cancer. 2024 Dec 11. doi: 10.1002/cncr.35655.
    PubMed     Abstract available
    
    
    November 2024
29. NIERENGARTEN MB
    Common strategy to diagnose endometrial cancer may not be reliable for Black women.
    Cancer. 2024;130:3783.
    PubMed    
    
    
    
30. NIERENGARTEN MB
    Women with more severe forms of endometriosis have a nearly 10-fold higher risk of ovarian cancer.
    Cancer. 2024;130:3784.
    PubMed    
    
    
    October 2024
31. KONDO T, Matsuki E, Takaku T, Watanabe N, et al
    Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Cancer. 2024 Oct 30. doi: 10.1002/cncr.35611.
    PubMed     Abstract available
    
    
    
32. JOHNSON HM, Song J, Warneke CL, Martinez AL, et al
    Outcomes of patients treated with chemotherapy for breast cancer during pregnancy compared with nonpregnant breast cancer patients treated with systemic therapy.
    Cancer. 2024 Oct 29. doi: 10.1002/cncr.35619.
    PubMed     Abstract available
    
    
    
33. WILSON EM, Huang R, Jones KD, Hagemann IS, et al
    Challenges in implementation of molecular classification in early stage endometrial cancer-An NRG Oncology cooperative group mixed-methods study.
    Cancer. 2024 Oct 17. doi: 10.1002/cncr.35596.
    PubMed     Abstract available
    
    
    
34. NIERENGARTEN MB
    Excellent outcomes with radiation alone for localized recurrences of endometrial cancer.
    Cancer. 2024;130:3400.
    PubMed    
    
    
    September 2024
35. MEGHANI K, Grover S
    Reply to "Assessing the impact of HIV status on cervical cancer treatment outcomes in Botswana: A commentary".
    Cancer. 2024 Sep 10. doi: 10.1002/cncr.35553.
    PubMed    
    
    
    
36. JEYARAJ G
    Assessing the impact of HIV status on cervical cancer treatment outcomes in Botswana: A commentary.
    Cancer. 2024 Sep 10. doi: 10.1002/cncr.35545.
    PubMed    
    
    
    August 2024
37. SULLIVAN MW, Graves S, Adkoli A, Zhou Q, et al
    Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer.
    Cancer. 2024 Aug 16. doi: 10.1002/cncr.35523.
    PubMed     Abstract available
    
    
    
38. ISSAKA RB, Ibekwe LN, Todd KW, Burnett-Hartman AN, et al
    Association between racial residential segregation and screening uptake for colorectal and cervical cancer among Black and White patients in five US health care systems.
    Cancer. 2024 Aug 9. doi: 10.1002/cncr.35514.
    PubMed     Abstract available
    
    
    July 2024
39. PEREZ L, Dioun S, Primiano M, Blank SV, et al
    Considering screening for hereditary cancer syndromes at the time of obstetrical prenatal carrier screening.
    Cancer. 2024 Jul 22. doi: 10.1002/cncr.35480.
    PubMed    
    
    
    
40. MACKAY H, Fernandes I
    Cell-free DNA in recurrent and metastatic endometrial cancer: The future is now? Promises and potential pitfalls.
    Cancer. 2024 Jul 10. doi: 10.1002/cncr.35448.
    PubMed    
    
    
    
41. ELGHAZALY H, Azim HA, Rugo HS, Cameron D, et al
    Tailoring neo/adjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations.
    Cancer. 2024 Jul 10. doi: 10.1002/cncr.35389.
    PubMed     Abstract available
    
    
    
42. BANERJEE S, Hasson SP
    Top advances of the year: Immunotherapy in endometrial cancer.
    Cancer. 2024 Jul 4. doi: 10.1002/cncr.35417.
    PubMed     Abstract available
    
    
    
43. NIERENGARTEN MB
    Significant overall survival benefit with dostarlimab plus chemotherapy in advanced endometrial cancer.
    Cancer. 2024;130:2245.
    PubMed    
    
    
    
44. NIERENGARTEN MB
    Favorable overall survival trend with pembrolizumab plus chemotherapy for endometrial cancer.
    Cancer. 2024;130:2246.
    PubMed    
    
    
    June 2024
45. BEAVIS AL, Wethington SL, Yu R, Topel KM, et al
    Differential utilization of the online patient portal for completion of health-related social needs screening during routine gynecologic cancer care.
    Cancer. 2024 Jun 29. doi: 10.1002/cncr.35376.
    PubMed     Abstract available
    
    
    
46. 
    Erratum to "Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials".
    Cancer. 2024 Jun 7. doi: 10.1002/cncr.35344.
    PubMed    
    
    
    
47. BLANC-DURAND F, Camilleri GM, Bayle A, Aldea M, et al
    Clinical utility of comprehensive liquid molecular profiling in patients with advanced endometrial cancer.
    Cancer. 2024 Jun 2. doi: 10.1002/cncr.35381.
    PubMed     Abstract available
    
    
    May 2024
48. LOGGERS ET, Chugh R, Federman N, Hartner L, et al
    Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study.
    Cancer. 2024 May 4. doi: 10.1002/cncr.35324.
    PubMed     Abstract available
    
    
    April 2024
49. DUSKA LR, Podwika SE, Randall LM
    Top advances of the year: Cervical cancer.
    Cancer. 2024 Apr 23. doi: 10.1002/cncr.35334.
    PubMed     Abstract available
    
    
    
50. STERPETTI AV, Gabriele R, Iannone I, Dimarzo L, et al
    National organized screening programs for breast, colorectal, and cervical cancer reduce socioeconomic disparities, but it is not enough.
    Cancer. 2024 Apr 20. doi: 10.1002/cncr.35335.
    PubMed    
    
    
    
51. RUAN Y, Heer E, Brenner DR
    Reply to "National organized screening programs for breast, colorectal, and cervical cancer reduce socioeconomic disparities, but it is not enough".
    Cancer. 2024 Apr 20. doi: 10.1002/cncr.35339.
    PubMed    
    
    
    
52. NIERENGARTEN MB
    Promising new treatment approaches for locally advanced cervical cancer.
    Cancer. 2024;130:1192.
    PubMed    
    
    
    
53. ERICKSON BK, Slomovitz B, Powell M, Eskander RN, et al
    Top advances of the year: Uterine cancer.
    Cancer. 2024 Apr 15. doi: 10.1002/cncr.35321.
    PubMed     Abstract available
    
    
    March 2024
54. MEGHANI K, Puri P, Bazzett-Matabele L, Vuylsteke P, et al
    Significance of HIV status in cervical cancer patients receiving curative chemoradiation therapy, definitive radiation alone, or palliative radiation in Botswana.
    Cancer. 2024 Mar 26. doi: 10.1002/cncr.35289.
    PubMed     Abstract available
    
    
    
55. LEE H, Baeker Bispo J, Pal Choudhury P, Wiese D, et al
    Factors contributing to differences in cervical cancer screening in rural and urban community health centers.
    Cancer. 2024 Mar 25. doi: 10.1002/cncr.35265.
    PubMed     Abstract available
    
    
    
56. MICHEL AD, Fontenot HB, Fuzzell L, Brownstein NC, et al
    Attitudes toward the American Cancer Society's 2020 cervical cancer screening guidelines: A qualitative study of a national sample of US clinicians.
    Cancer. 2024 Mar 4. doi: 10.1002/cncr.35269.
    PubMed     Abstract available
    
    
    February 2024
57. LIU YL, Weigelt B
    A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair-deficient and microsatellite instability-high endometrial cancers.
    Cancer. 2024 Feb 29. doi: 10.1002/cncr.35267.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.